



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Operations Office

Date: December 10, 2010

To: Primary Clinical Research Associates

From: Sara M. Braun
Research Protocol Specialist III

Re: N0775, A Randomized Phase II Trial of Temozolomide (TMZ) and Avastin® or
ABI-007/Carboplatin (CBDCA) and Avastin® in Patients with Unresectable Stage IV Malignant
Melanoma

Attached are updated form(s) for this protocol. Edits are as follows:

CRF Title	Brief Description of Edit
Adverse Event Form	<ul style="list-style-type: none">Added "CTCAE v3.0" to CTC Adverse Events term on all 3 pages.
Baseline Adverse Events Form	<ul style="list-style-type: none">Added "CTCAE v3.0" to CTC Adverse Events term

If you have any questions, please feel free to contact me.

Thank you.